AU2002211999A1 - Haemophilus influenzae antigens and corresponding DNA fragments - Google Patents

Haemophilus influenzae antigens and corresponding DNA fragments

Info

Publication number
AU2002211999A1
AU2002211999A1 AU2002211999A AU1199902A AU2002211999A1 AU 2002211999 A1 AU2002211999 A1 AU 2002211999A1 AU 2002211999 A AU2002211999 A AU 2002211999A AU 1199902 A AU1199902 A AU 1199902A AU 2002211999 A1 AU2002211999 A1 AU 2002211999A1
Authority
AU
Australia
Prior art keywords
polypeptide
seq
polynucleotide
nos
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211999A
Other languages
English (en)
Inventor
Bernard R Brodeur
Annie Charbonneau
France Couture
Josee Hamel
Denis Martin
Catherine Ouellet
Mireille Tremblay
Catherine Vayssier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
Original Assignee
Shire BioChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire BioChem Inc filed Critical Shire BioChem Inc
Publication of AU2002211999A1 publication Critical patent/AU2002211999A1/en
Assigned to ID BIOMEDICAL CORPORATION reassignment ID BIOMEDICAL CORPORATION Request for Assignment Assignors: SHIRE BIOCHEM INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU2002211999A 2000-10-02 2001-10-02 Haemophilus influenzae antigens and corresponding DNA fragments Abandoned AU2002211999A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23671200P 2000-10-02 2000-10-02
US60/236,712 2000-10-02
PCT/CA2001/001402 WO2002028889A2 (en) 2000-10-02 2001-10-02 Haemophilus influenzae antigens and corresponding dna fragments

Publications (1)

Publication Number Publication Date
AU2002211999A1 true AU2002211999A1 (en) 2002-04-15

Family

ID=22890628

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211999A Abandoned AU2002211999A1 (en) 2000-10-02 2001-10-02 Haemophilus influenzae antigens and corresponding DNA fragments

Country Status (13)

Country Link
US (1) US20040171802A1 (pt)
EP (4) EP2088197B8 (pt)
JP (3) JP2004509647A (pt)
AU (1) AU2002211999A1 (pt)
BR (1) BR0114403A (pt)
CA (1) CA2424275A1 (pt)
CY (2) CY1114614T1 (pt)
DK (2) DK2270171T5 (pt)
ES (2) ES2588023T3 (pt)
HK (1) HK1152965A1 (pt)
PT (2) PT2270171E (pt)
SI (2) SI2270171T1 (pt)
WO (1) WO2002028889A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018514A1 (en) * 2002-08-22 2004-03-04 Id Biomedical Corporation Polypeptides of nontypeable haemophilus influenzae and corresponding dna fragments
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CA2618554C (en) 2005-08-10 2017-03-07 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
BRPI0707154B8 (pt) * 2006-01-17 2022-12-20 Forsgren Arne composição de vacina
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
AU2013254751B2 (en) * 2012-04-26 2017-12-14 Glaxosmithkline Biologicals S.A. Antigens and antigen combinations
MX2017015110A (es) 2015-06-05 2018-05-07 Firmenich & Cie Microcapsulas con alta deposicion en superficies.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
JPH11501520A (ja) * 1995-04-21 1999-02-09 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド インフルエンザ菌Ｒｄゲノムのヌクレオチド配列、そのフラグメント及びその使用
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene

Also Published As

Publication number Publication date
EP2088197A2 (en) 2009-08-12
CY1117746T1 (el) 2017-05-17
SI2270171T1 (sl) 2013-12-31
EP2088197A3 (en) 2011-12-21
ES2588023T3 (es) 2016-10-28
PT2088197T (pt) 2016-08-01
US20040171802A1 (en) 2004-09-02
EP1322762A2 (en) 2003-07-02
ES2435923T3 (es) 2013-12-26
DK2270171T5 (da) 2013-11-18
PT2270171E (pt) 2013-11-05
DK2270171T3 (da) 2013-10-14
EP2270171A3 (en) 2011-04-27
EP2270171A2 (en) 2011-01-05
CA2424275A1 (en) 2002-04-11
WO2002028889A3 (en) 2003-04-10
EP2088197B8 (en) 2016-07-20
SI2088197T1 (sl) 2016-11-30
JP2004509647A (ja) 2004-04-02
BR0114403A (pt) 2004-02-17
EP2270171B1 (en) 2013-09-04
EP2280071A3 (en) 2011-04-27
EP2280071A2 (en) 2011-02-02
JP2011231114A (ja) 2011-11-17
EP2088197B1 (en) 2016-06-08
JP2009149642A (ja) 2009-07-09
WO2002028889A2 (en) 2002-04-11
HK1152965A1 (en) 2012-03-16
CY1114614T1 (el) 2016-10-05
DK2088197T3 (en) 2016-08-01

Similar Documents

Publication Publication Date Title
JP2011231114A (ja) ヘモフィルス・インフルエンゼ抗原及び対応ｄｎａ断片
US20090074807A1 (en) Moraxella (branhamella) catarrhalis antigens
AU2007202270B2 (en) Haemophilus influenzae antigens and corresponding DNA fragments
AU2011253696B8 (en) Haemophilus influenzae antigens and corresponding DNA fragments
AU2002302236A1 (en) Moraxella(Branhamella) catarrhalis antigens
EP1399563B1 (en) Moraxella (branhamella) catarrhalis antigens
US7329500B2 (en) Moraxella (Branhamella) catarrhalis polypeptides and corresponding DNA fragments
US7410648B2 (en) Polypeptides of Moraxella (Branhamella) catarrhalis
AU2002325109A1 (en) Moraxella (branhamella) catarrhalis polypeptides and corresponding DNA fragments
AU2002344869A1 (en) Moraxella (branhamella) catarrhalis antigens
WO2004018514A1 (en) Polypeptides of nontypeable haemophilus influenzae and corresponding dna fragments
WO2004009621A2 (en) Polypeptides of nontypeable haemophilus influenzae

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ID BIOMEDICAL CORPORATION

Free format text: FORMER APPLICANT(S): SHIRE BIOCHEM INC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted